View More Recent Stories
-
Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 45c ; Offers Guidance
-
Biogen (BIIB): FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
-
7 top biotech picks for 2025 according to Wells Fargo
-
Piper Sandler Reiterates Overweight Rating on Ionis Pharmaceuticals (IONS) Following FDA Approval
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) on TRYNGOLZA approval
-
Ionis Pharmaceuticals (IONS) FDA approves TRYNGOLZA for adults with familial chylomicronemia syndrome
-
Ionis Pharmaceuticals' (IONS) tryngolza approved by FDA for adult patients with familial chylomicronemia syndrome
-
Ionis Pharmaceuticals (IONS) Halted, News Pending
-
Ionis Pharmaceuticals (IONS) Added to Raymond James Analyst Current Favorite List, Chart Industries (GTLS) Removed
-
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 17c
-
Ionis Pharmaceuticals (IONS) Announces Pivotal Phase 3 Trial Design for ION582
-
Ionis Pharmaceuticals (IONS) announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
-
Ionis Pharmaceuticals (IONS) reports WAINZUA recommended for approval in the EU by CHMP
-
Laidlaw Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Biogen (BIIB): New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
-
Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at ACAAI
-
Ionis Pharmaceuticals (IONS): Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) Prices 11.5M Share Offering at $43.50/sh
-
Ionis Pharmaceuticals (IONS) Announces Proposed $500M Share Offering
-
Biogen (BIIB) Reports Positive Topline Results from Study of Higher Dose Regimen of Nusinersen
-
BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
-
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 48c
-
RBC's biotech survey shows investors more bearish vs. last time
-
Leerink Partners Upgrades Ionis Pharmaceuticals (IONS) to Outperform
-
Ionis Pharmaceuticals (IONS) PT Raised to $59 at TD Cowen
-
BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
-
Goldman Sachs Reiterates Sell Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
-
Jefferies Double Upgrades Ionis Pharmaceuticals (IONS) to Buy
-
Ionis Pharmaceuticals (IONS) PT Raised to $53 at Stifel
-
Ionis Pharmaceuticals (IONS) announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
-
TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
Ionis Pharmaceuticals (IONS) expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Bernstein SocGen Group Upgrades Ionis Pharmaceuticals (IONS) to Market Perform
